Abstracts tagged "Infection"

Abstract Number: 2133 • ACR Convergence 2025
Examination of HLA-DRB1*15-linked Candidate Antigens in Still’s Disease with and without Lung Disease and Features of Drug Hypersensitivity
Dale Kobrin¹, Garrett Brown², Mariana Correia Marques¹, Carol Lake³, Michelle Millwood⁴, Lisa Workman⁵, Monica Lawrence⁵, Zuoming Deng⁶, Sanchita Das² and Michael Ombrello⁷, ¹Translational Genetics and Genomics Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Department of Laboratory Medicine, National Institutes of Health, Bethesda, MD, ³NIH, GAITHERSBURG, MD, ⁴National Institutes of Health (NIH), Bethesda, MD, ⁵Division of Asthma, Allergy, and Immunology, University of Virginia School of Medicine, Charlottesville, VA, ⁶Biodata Mining and Discovery Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁷National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), North Bethesda, MD
Background/Purpose: Lung disease in systemic juvenile idiopathic arthritis and adult-onset Still’s disease (Still’s-LD) is a severe manifestation that strongly associates with features of drug hypersensitivity…
Abstract Number: 1157 • ACR Convergence 2025
Safety and Tolerability of a Recombinant Zoster Vaccine in Patients with Inflammatory Rheumatic Musculoskeletal Diseases: A Prospective Longitudinal Study over 12 Months
Ella Steiner¹, Ioana Andreica², Stefanie Reale³, Gianna Chierego⁴, Philipp Köhler⁵, Sonja Zapke⁴, Benjamin Wilde⁶, David Kiefer⁷, Philipp Sewerin², Hilal Kavruk⁵, Dimitra Karagkiozidou⁵, Panagiotis Ermeidis⁵, Barbara Guminski⁵, Andreas Kribben⁶, Jürgen Braun⁸, Xenofon Baraliakos⁹ and Uta Kiltz⁹, ¹Rheumazentrum Ruhrgebiet Herne, Herne, Nordrhein-Westfalen, Germany, ²Rheumazentrum Ruhrgebiet Herne; Ruhr-Universität Bochum, Germany, Herne, Germany, ³Rheumazentrum Ruhrgebiet, Herne, Nordrhein-Westfalen, Germany, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ⁶University Hospital, Nephrology, Essen, Essen, Germany, ⁷Private practice of rheumatology, Hattingen, Germany, ⁸Ruhr-University, Bochum, Germany; and Rheumatologische Versorgungszentrum (RVZ) Steglitz, Berlin, Germany, ⁹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: Herpes zoster (HZ) is common among older adults, with a lifetime risk of 25%. The risk is particularly increased in individuals with immunosuppression such…
Abstract Number: 0206 • ACR Convergence 2025
Prospective Controlled Study of Humoral Response to Recombinant Zoster Vaccine in Cyclophosphamide-Treated Autoimmune Rheumatic Disease Patients: No Additional Impairment Compared to Other Immunosuppressive Therapies
Nadia Emi Aikawa¹, Julia Medeiros², Sandra G Pasoto³, Ana C Medeiros-Ribeiro³, Luciana Parente Costa Seguro⁴, Ana Paula Luppino-Assad⁵, Emily Figueiredo Neves Yuki⁶, Lissiane Guedes⁷, Clovis Artur Silva⁸ and Eloisa Bonfa⁴, ¹Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, São Paulo, Brazil, ²Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ⁴Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, ⁵Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SAO PAULO, Brazil, ⁶Faculdade de Medicina da USP, São Paulo, São Paulo, Brazil, ⁷Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, ⁸University of São Paulo, São Paulo, São Paulo, Brazil
Background/Purpose: Recombinant zoster vaccine (RZV), represents a major advancement in the prevention of herpes zoster in autoimmune rheumatic diseases (ARD) patients. However, RVZ efficacy depends…
Abstract Number: 2044 • ACR Convergence 2025
Infections and Associated Mortality in VEXAS Syndrome: A Systematic Review and Meta-Analysis
Oyku Zeynep Avarbek¹, Ozlem Arikan², Aysu Tatari³, Furkan Ak⁴, Bengisu Gur⁵, Sinem Nursel Duzenci⁶, Yasin Taha Tuncar⁷, Mustafa Sivri⁸, Mustafa Ovayolu⁹ and Miray Kurtca¹⁰, ¹Bezmialem Vakif University, Faculty of Medicine, Istanbul, Türkiye, Istanbul, Turkey, ²Istanbul Aydin University, Faculty of Medicine, Istanbul, Türkiye, Istanbul, Turkey, ³Pamukkale University, Faculty of Medicine, Denizli, Türkiye, Denizli, Turkey, ⁴Sofia University St. Kliment Ohridski, Faculty of Medicine, Sofia, Bulgaria, Sofia, Bulgaria, ⁵Istanbul University, Istanbul Faculty of Medicine, Istanbul, Türkiye, Istanbul, Turkey, ⁶Balikesir University, Faculty of Medicine, Balikesir, Türkiye, Balikesir, Turkey, ⁷Akdeniz University, Faculty of Medicine, Antalya, Türkiye, Istanbul, Turkey, ⁸Gazi University, Department of Emergency Medicine, Ankara, Türkiye, Ankara, Turkey, ⁹Hacettepe University, Faculty of Medicine, Ankara, Türkiye, Ankara, Turkey, ¹⁰Richmond University Medical Center, Department of Internal Medicine, Staten Island, NY
Background/Purpose: Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is a late-onset, monogenic autoinflammatory disorder driven by somatic mutations in the UBA1 gene of hematopoietic…
Abstract Number: 1120 • ACR Convergence 2025
Synergistic Effects of IL-17F and IL-17A on Neutrophil Chemotaxis: Increased Risk of Candidiasis with Dual Blockade of IL-17A and IL17-F
Siba Raychaudhuri¹, Disha Chakraborty², Christine Abria² and Smriti K Raychaudhuri³, ¹UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, ²Sacramento VA Medical Center, Mather, CA, ³Sacramento VA Medical Center, Davis, CA
Background/Purpose: IL-17 is primarily secreted by Th17 cells. The IL-17 family has 6 related cytokines (IL-17A to IL17F); IL-17A and IL-17F, being key proinflammatory mediators.…
Abstract Number: 0205 • ACR Convergence 2025
Implementation of the Varicella Zoster virus vaccine and its Real-World effectiveness
Laura Mas Sanchez¹, ELENA GRAU GARCIA², Carlos Valera Ribera³, Pablo Muñoz-Martínez⁴, Daniel Ramos Castro⁵, Alba Maria Torrat Noves⁶, Belen Villanueva Manes⁷, Iago Alcántara Álvarez⁸, Miguel Simeo Vinaixa⁹, Andres Perez Hurtado¹⁰ and José Andrés Román Ivorra¹¹, ¹Hospital Universitari i Politecnic La Fe, València, Spain, ²HUP La Fe, Valencia, Comunidad Valenciana, Spain, ³Hospital Universitario Doctor Peset, València, Spain, ⁴Hospital Universitario y Politécnico La Fe, Sagunto, Spain, ⁵Hospital Universitari i Politecnic La Fe, Valencia, Spain, ⁶Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Spain, ⁷Hospital La Fe, València, Spain, ⁸Hospital Universitari i Politénic La Fe, València, Spain, ⁹Rheumatology Department. HUP La Fe, Valencia, Spain, ¹⁰Hospital Universitario y Politècnico La Fe, València, Comunidad Valenciana, Spain, ¹¹Hospital Universitari i Politècnic La Fe, Valencia, Spain
Background/Purpose: In 2023, Spain approved the inactivated varicella zoster virus (VZV) vaccine in individuals over 50 years of age with immunosuppressive conditions, including rheumatology patients…
Abstract Number: 2039 • ACR Convergence 2025
To Hold or Not to Hold: Variability in Management of DMARDs in the Setting of Acute Infections – A Survey of Rheumatologists
Mollie Gellman¹, Medhasweta Sen², Ari Schwartz³, Peter Merkel⁴ and Nadine Mbuyi⁵, ¹Montefiore Medical Center, Bronx, NY, ²University of Virginia, Charlottesville, VA, ³Rheumatology Consultants PC, Brockton, MA, ⁴University of Pennsylvania, Philadelphia, PA, ⁵George Washington University, Washington, DC
Background/Purpose: Disease-modifying antirheumatic drugs (DMARDs) vary widely in their immunosuppressive activity. Guidance on managing DMARDs during acute infections is limited, particularly regarding when to hold…
Abstract Number: 1090 • ACR Convergence 2025
Quantitative Immunoglobulin Screening Prior to Rituximab Initiation: A Retrospective Cohort Study
Amelia Khoo and Anokhi Saklecha, Yale University, New Haven, CT
Background/Purpose: Rituximab, a monoclonal antibody which binds to the CD20 antigen of B cells, is used in the treatment of many rheumatologic conditions. Due to…
Abstract Number: 0204 • ACR Convergence 2025
Immunogenicity and safety summary for the chikungunya virus-like particle vaccine development programme
Lauren Tindale¹, Jason Richardson¹, Deborah Anderson¹, Jason Mendy², Sufia Muhammad², Tobi Loreth¹, Victoria Jenkins³, Krystal Valenzuela⁴, Benedetto Simone⁵, Patrick Ajiboye² and Lisa Bedell⁴, ¹Bavarian Nordic Canada Inc., Toronto, Canada, ²Bavarian Nordic, Inc., San Diego, ³Bavarian Nordic Belgium, Brussels, Belgium, ⁴Bavarian Nordic, Inc., Durham, ⁵Bavarian Nordic Berna GmbH, Thoerishaus, Switzerland
Background/Purpose: Chikungunya virus (CHIKV) is a threat to public health and a risk for travellers to endemic countries. Typical acute symptoms include fever, arthralgia, myalgia,…
Abstract Number: 1902 • ACR Convergence 2025
Investigating Factors Associated With Respiratory Syncytial Virus Vaccination and Breakthrough Infection Among Patients With Systemic Autoimmune Rheumatic Diseases
Natalie Davis¹, Jiaqi Wang², Xiaosong Wang³, Liya Sisay Getachew⁴, Lauren O'Keeffe⁵, Grace Qian⁵, Kevin Mueller⁵, Madison Negron⁶, Alene Saavedra⁵, Naomi Patel⁷ and Jeffrey Sparks⁴, ¹Brigham and Women's Hospital, Brookline, MA, ²Massachusetts General Hospital, BOston, ³Brigham and Women's Hospital, Natick, MA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Boston, ⁶Harvard Extension School, Medford, MA, ⁷Massachusetts General Hospital, Boston, MA
Background/Purpose: Respiratory syncytial virus (RSV) vaccines were approved starting in May 2023 and are recommended by the US CDC to adults aged 60 years or…
Abstract Number: 1065 • ACR Convergence 2025
Age of Disease Onset and Risk of Serious Infection with anti-TNF Use in Older Adults with Rheumatoid Arthritis
Jiha Lee¹, Sofia Pedro² and Kaleb Michaud³, ¹University of Michigan, Ann Arbor, MI, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Older age is a recognized risk factor for serious infection (SI) associated with anti-TNF therapy in rheumatoid arthritis (RA). Among older adults with RA,…
Abstract Number: 0202 • ACR Convergence 2025
Saudi Society for Rheumatology Consensus Recommendation on Vaccination Strategies in Adults Saudi with Autoimmune Rheumatic Disorders
Fahidah Alenzi¹, Hanan Alrayes², Khawla K Alghanim³, FEHAID ALANAZI⁴, Mohammed Attar⁵, Mansour Alazmi⁶, Suzan Attar⁷, Nisreen Alsherbeeni⁸, Azzam Alotaibi⁹ and Fayssal M Farahat¹⁰, ¹Associate Professor and Consultant Rheumatology, Department of Internal Medicine, College of Medicine, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia, Riyadh, Saudi Arabia, ²Riyadh Military - Prince Soltan Military Medical City ( PSMMC ) - Olaya, Riyadh, Saudi Arabia, ³Consultant Rheumatologist and lupus specialist, Department of Internal Medicine, Rheumatology Unit, King Fahad Military Medical Complex, Dhahran, Saudi Arabia, Dhahran, Saudi Arabia, ⁴King Khaled university Hospital, Riyadh, Saudi Arabia, ⁵Al hada armed forces hospital, Taif, Saudi Arabia, ⁶Internal Medicine and Rheumatology Consultant , Prince Mohammed Medical City, Aljouf , Saudi Arabia, Sakaka- Aljouf, Saudi Arabia, ⁷King Abdulaziz University, Saudi Arabia, Jeddah, Saudi Arabia, ⁸Consultant Internal Medicine & Infectious Disease, Infectious Disease Division Department of Medicine at Prince Sultan Military Medical City, Riyadh, Saudi Arabia, ⁹Consultant Internal Medicine, Allergy, and Immunology, Division of Allergy and Immunology, Department of Medicine at Prince Sultan Military Medical City, Riyadh, Saudi Arabia, ¹⁰Infection Prevention and Control Program, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, P.O. Box ²²⁴⁹⁰, Riyadh ¹¹⁴²⁶, Saudi Arabia; College of Public Health and Health Informatics, King Saud bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs, P.O. Box ³⁶⁶⁰, Riyadh ¹¹⁴⁸¹, Saudi Arabia; King Abdullah International Medical Research Center, Ministry of National Guard Health Affairs, P.O. Box ³⁶⁶⁰, Riyadh ¹¹⁴⁸¹, Saudi Arabia, Riyadh, Saudi Arabia
Background/Purpose: Patients with autoimmune inflammatory rheumatic diseases (AIIRD) are at increased risk of infections due to both immune system dysfunction and the use of immunosuppressive…
Abstract Number: 1879 • ACR Convergence 2025
Infections in Hospitalized Patients With and Without Psoriatic Arthritis (2016–2021): A National Inpatient Sample Study
Ayema Haque, Ana Salas, Bruna Diniz, Harshank Patel and Philip Kroth, Western Michigan University School of Medicine, Kalamazoo, MI
Background/Purpose: Psoriatic arthritis (PsA) is a chronic, immune-mediated inflammatory disorder affecting up to 30% of psoriasis patients and is associated with increased infection risk. This…
Abstract Number: 1061 • ACR Convergence 2025
Screening for Hepatitis B in a Veterans Health Administration Subpopulation with Rheumatological Disease Prior to Initiating Immunosuppressive Therapy: a retrospective study on testing and treatment within the Black American population from the VAMC in Memphis, TN
Daniel Austin¹, Beenish Zulfiqar², Akhil Adla¹, Jeffrey Zuber² and Joshua Sullivan³, ¹University of Tennessee Health Science Center, Memphis, TN, ²University of Tennessee Health Science Center & Lt. Col. Luke J. Weathers, Jr. VA Medical Center, Memphis, TN, Memphis, TN, ³Lt. Col. Luke J. Weathers, Jr. VA Medical Center, Memphis, TN, Memphis, TN
Background/Purpose: Hepatitis B virus (HBV) screening is insufficiently completed prior to initiation of immunosuppressive therapy nationwide. Various factors including alert fatigue, provider mistakes, non-compliance, and…
Abstract Number: 0201 • ACR Convergence 2025
Real-World study of immunogenicity and safety of the adjuvant recombinant vaccine against varicella zoster virus in patients with immune-mediated inflammatory diseases treated with Janus Kinase Inhibitors in comparison with healthy individuals
Ana Victoria Esteban Vázquez¹, Martina Steiner², Cristina Vergara², Elisabet Castañeda Estévez³, Maria Beatriz Paredes Romero⁴, Isabel De La Camara-Fernandez¹, Laura Trives¹, Tatiana Cobo¹, Patricia Richi⁵, Maria liz Romero⁵, Marta De San Segundo³, Antonio Sanchis³, Carolina Marín⁶, Maria Teresa Navio Marco⁷ and Santiago Muñoz¹, ¹Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, Madrid, Spain, ²Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, Madrid, Madrid, Spain, ³Hospital Universitario Infanta Sofía, Madrid, Spain, ⁴Infanta Sofía University Hospital, Madrid, Spain, ⁵Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, San Sebastian de Los Reyes, Madrid, Spain, ⁶Department of Rheumatology, Hospital Universitario Infanta Leonor / Universidad Complutense de Madrid, Madrid, Spain, Madrid, Spain, ⁷Infanta Leonor Universitary Hospital, Madrid, Spain
Background/Purpose: Patients with immune-mediated inflammatory diseases (IMIDs) receiving Janus Kinase Inhibitors (JAKi) are at increased risk of herpes zoster reactivation. The adjuvanted recombinant zoster vaccine…

1
2
3
…
36
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].